Objective:To evaluate to the efficacy and safety of Shenqi Fuzheng Injection(SFI)combined with chemotherapy in the treatment of acute leukemia(AL)by meta-analysis.Methods:Pub Med,Cochrane library,Embase,Sino Med,China...Objective:To evaluate to the efficacy and safety of Shenqi Fuzheng Injection(SFI)combined with chemotherapy in the treatment of acute leukemia(AL)by meta-analysis.Methods:Pub Med,Cochrane library,Embase,Sino Med,China National Knowledge Infrastructure(CNKI),VIP Journal Integration Platform,Wanfang Database were searched from establishment to November 1,2018.The randomized controlled trials(RCTs)of SFI combined with chemotherapy in the treatment of AL were included.The Cochrane risk assessment form(Rev Man 5.1)was used to evaluate the quality of included studies.Results:A total of 14 RCTs and 1,088 patients was included.The quality evaluation was mostly low risk or unclear.Meta-analysis showed that compared with chemotherapy alone,SFI combined with chemotherapy can improve the total clinical effective rate in patients with AL(RR=1.15,95%CI:1.056–1.177;P=0.0001),and relieve adverse reactions caused by chemotherapy drugs,including infection(RR=0.561,95%CI:0.397–0.792;P=0.001),nausea and vomiting(RR=0.662,95%CI:0.524–0.835;P=0.001),bleeding(RR=0.548,95%CI:0.39–0.768;P=0.0001),cardiotoxicity(RR=0.230,95%CI:0.080–0.660;P=0.006)and hyperhidrosis(RR=0.348,95%CI:0.208–0.581;P=0.0001).The incidence rates of adverse reactions in SFI combined with chemotherapy group were significantly lower than that of the chemotherapy alone group(P<0.01).Conclusions:Shenqi Fuzheng Injection combined with chemotherapy has good efficacy and safety for AL,and it can alleviate the adverse reactions caused by chemotherapy.However,subject to the limitations of the methodological quality of the literature,the conclusions of this study need to be further verified by large-scale and multi-center RCTs.展开更多
目的 探讨参芪扶正注射液联合血液灌流对急性胰腺炎患者的血清炎症因子的影响及心肌保护作用。方法 前瞻性选取84例急性胰腺炎患者,随机将其分为研究组和对照组。全部患者给予常规对症治疗,对照组采用血液灌流治疗,研究组在对照组基础...目的 探讨参芪扶正注射液联合血液灌流对急性胰腺炎患者的血清炎症因子的影响及心肌保护作用。方法 前瞻性选取84例急性胰腺炎患者,随机将其分为研究组和对照组。全部患者给予常规对症治疗,对照组采用血液灌流治疗,研究组在对照组基础上采用参芪扶正注射液治疗。检测两组患者治疗前后生化指标;采用急性生理与慢性健康评分(APACHE Ⅱ评分)评估患者的病情状态;床旁急性胰腺炎严重度评分(BISAP评分)评估患者的病情严重程度。检测两组患者治疗前后血清炎症因子[C反应蛋白(CRP)、白介素6(IL-6)、肿瘤坏死因子(TNF-α)、白介素8(IL-8)]和血清心肌损伤标志物[肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白I(cTnI)、乳酸脱氢酶1(LDH1)、天冬氨酸氨基转移酶(AST)]的水平。结果 两组患者治疗后的血淀粉酶、血脂肪酶明显降低,血钙、血白蛋白明显升高( P <0.05);治疗后,研究组的的血淀粉酶、血脂肪酶比对照组低,血钙、血白蛋白比对照组高,差异有统计学意义( P <0.05);两组治疗后的CRP、IL-6、TNF-α、IL-8明显降低( P <0.05);治疗后,研究组的CRP、IL-6、TNF-α、IL-8低于对照组,差异有统计学意义( P <0.05);两组治疗后的CK-MB、cTnI、LDH1、AST明显降低( P <0.05);治疗后,研究组的CK-MB、cTnI、LDH1、AST低于对照组,差异有统计学意义( P <0.05);两组治疗后的APACHE Ⅱ评分、BISAP评分明显降低( P <0.05);研究组治疗后的APACHE Ⅱ评分、BISAP评分低于对照组,差异有统计学意义( P <0.05)。结论 在血流灌流治疗的基础上联合参芪扶正注射液能显著改善急性胰腺炎患者病情,进一步降低急性胰腺炎患者的血清炎症因子的水平,对心肌具有一定保护作用。展开更多
基金Supported by Science and Technology Fund Project of Health and Family Planning Commission of Guizhou Province(No.gzwjkj2019-2-006)the Science and Technology Plan Project of Qiannan Prefecture[Qiannan Keheshezi(2018)No.36]。
文摘Objective:To evaluate to the efficacy and safety of Shenqi Fuzheng Injection(SFI)combined with chemotherapy in the treatment of acute leukemia(AL)by meta-analysis.Methods:Pub Med,Cochrane library,Embase,Sino Med,China National Knowledge Infrastructure(CNKI),VIP Journal Integration Platform,Wanfang Database were searched from establishment to November 1,2018.The randomized controlled trials(RCTs)of SFI combined with chemotherapy in the treatment of AL were included.The Cochrane risk assessment form(Rev Man 5.1)was used to evaluate the quality of included studies.Results:A total of 14 RCTs and 1,088 patients was included.The quality evaluation was mostly low risk or unclear.Meta-analysis showed that compared with chemotherapy alone,SFI combined with chemotherapy can improve the total clinical effective rate in patients with AL(RR=1.15,95%CI:1.056–1.177;P=0.0001),and relieve adverse reactions caused by chemotherapy drugs,including infection(RR=0.561,95%CI:0.397–0.792;P=0.001),nausea and vomiting(RR=0.662,95%CI:0.524–0.835;P=0.001),bleeding(RR=0.548,95%CI:0.39–0.768;P=0.0001),cardiotoxicity(RR=0.230,95%CI:0.080–0.660;P=0.006)and hyperhidrosis(RR=0.348,95%CI:0.208–0.581;P=0.0001).The incidence rates of adverse reactions in SFI combined with chemotherapy group were significantly lower than that of the chemotherapy alone group(P<0.01).Conclusions:Shenqi Fuzheng Injection combined with chemotherapy has good efficacy and safety for AL,and it can alleviate the adverse reactions caused by chemotherapy.However,subject to the limitations of the methodological quality of the literature,the conclusions of this study need to be further verified by large-scale and multi-center RCTs.
文摘目的 探讨参芪扶正注射液联合血液灌流对急性胰腺炎患者的血清炎症因子的影响及心肌保护作用。方法 前瞻性选取84例急性胰腺炎患者,随机将其分为研究组和对照组。全部患者给予常规对症治疗,对照组采用血液灌流治疗,研究组在对照组基础上采用参芪扶正注射液治疗。检测两组患者治疗前后生化指标;采用急性生理与慢性健康评分(APACHE Ⅱ评分)评估患者的病情状态;床旁急性胰腺炎严重度评分(BISAP评分)评估患者的病情严重程度。检测两组患者治疗前后血清炎症因子[C反应蛋白(CRP)、白介素6(IL-6)、肿瘤坏死因子(TNF-α)、白介素8(IL-8)]和血清心肌损伤标志物[肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白I(cTnI)、乳酸脱氢酶1(LDH1)、天冬氨酸氨基转移酶(AST)]的水平。结果 两组患者治疗后的血淀粉酶、血脂肪酶明显降低,血钙、血白蛋白明显升高( P <0.05);治疗后,研究组的的血淀粉酶、血脂肪酶比对照组低,血钙、血白蛋白比对照组高,差异有统计学意义( P <0.05);两组治疗后的CRP、IL-6、TNF-α、IL-8明显降低( P <0.05);治疗后,研究组的CRP、IL-6、TNF-α、IL-8低于对照组,差异有统计学意义( P <0.05);两组治疗后的CK-MB、cTnI、LDH1、AST明显降低( P <0.05);治疗后,研究组的CK-MB、cTnI、LDH1、AST低于对照组,差异有统计学意义( P <0.05);两组治疗后的APACHE Ⅱ评分、BISAP评分明显降低( P <0.05);研究组治疗后的APACHE Ⅱ评分、BISAP评分低于对照组,差异有统计学意义( P <0.05)。结论 在血流灌流治疗的基础上联合参芪扶正注射液能显著改善急性胰腺炎患者病情,进一步降低急性胰腺炎患者的血清炎症因子的水平,对心肌具有一定保护作用。
